IDEAYA Biosciences (IDYA) Study result summary

Disease background and unmet need

• Uveal melanoma is a rare, aggressive cancer with poor prognosis and limited treatment options at all stages, with about 3,000 cases diagnosed annually in the U.S. and half progressing to metastatic disease.

• Median overall survival for metastatic cases is 10–12 months, with a five-year survival rate of 15–20%.

• Most patients are ineligible for the only approved systemic therapy, and liver metastasis is common.

• The majority of metastatic uveal melanoma patients are HLA-A*02:01-negative, who lack approved therapies and have poor prognosis.

Mechanism of action and therapeutic rationale

• Darovasertib is an oral, selective PKC inhibitor targeting the primary oncogenic pathway in over 95% of UM patients, often driven by GNAQ/11 mutations.

• In metastatic UM, darovasertib is combined with crizotinib, a CMET pathway inhibitor, to address metastatic spread and improve outcomes.

• The all-oral regimen aims to improve compliance, outcomes, and quality of life.

Study background, design, and patient population

• OptimUM-02 is a pivotal, global, randomized Phase 2/3 trial in first-line HLA-A2-negative metastatic uveal melanoma, enrolling 313–437 subjects randomized 2:1 to darovasertib plus crizotinib versus standard of care, including ipi/nivo or single-agent checkpoint inhibitors.

• The comparator arm reflected real-world practice, using ipilimumab plus nivolumab or pembrolizumab.

• The trial's primary endpoint was progression-free survival (PFS) by blinded independent central review, with overall survival (OS) as a key endpoint.

• Secondary endpoints included investigator-assessed PFS, overall response rate (ORR), duration of response, disease control rate, safety, and quality of life.

• The combination rationale was based on preclinical synergy between PKC inhibition (darovasertib) and MET inhibition (crizotinib).